Clinical Report: Effectiveness and Safety of Neoadjuvant Treatments in Prostate Cancer

Overview

This systematic review and network meta-analysis evaluates the efficacy and safety of neoadjuvant treatments for high-risk and locally advanced prostate cancer in elderly patients. Novel neoadjuvant hormonal therapy (NNHT) was found to be the most effective in improving pathological outcomes, despite a higher incidence of adverse events.

Background

High-risk and locally advanced prostate cancer presents significant treatment challenges, particularly in older adults. Neoadjuvant therapies are being explored to improve surgical outcomes, but their comparative efficacy and safety remain uncertain. Understanding the effectiveness of these treatments is crucial for optimizing patient care and guiding clinical decision-making.

Data Highlights

Key Findings

• NNHT ranked highest for improving positive surgical margin (PSM) rates.
• NNHT also showed significant post-treatment prostate-specific antigen (PSA) reduction.
• Despite its efficacy, NNHT was associated with the highest toxicity burden among treatments.
• Clinical downstaging was a notable secondary outcome of NNHT.
• The study included a network meta-analysis of 15 relevant trials.

Clinical Implications

Clinicians should consider the efficacy-toxicity trade-off when selecting neoadjuvant treatments for elderly patients with high-risk prostate cancer. NNHT may be prioritized in clinical trials aimed at evaluating long-term survival and safety outcomes.

Conclusion

NNHT emerges as the most effective neoadjuvant treatment for improving pathological outcomes in high-risk prostate cancer, though its associated toxicity necessitates careful patient selection and monitoring.

Related Resources & Content

1. Eastham et al, Journal of Clinical Oncology, 2020 -- Does Adding Neoadjuvant Chemohormonal Therapy to Surgery in Patients With Localized High-Risk Prostate Cancer Improve Biochemical Progression–Free Survival?
2. Clinical Trials Actively Recruiting Geriatric Oncology Patients, The ASCO Post, 2017 -- Clinical Trials Actively Recruiting Geriatric Oncology Patients
3. Springer, 2024 -- Influence of Lymph Node Count on Outcomes in Older and Younger Patients with T3-4/N+ Rectal Cancer After Neoadjuvant Treatment: A Retrospective Analysis
4. Mapping European Association of Urology Guideline Practice Across Europe, PubMed, 2023 -- Mapping European Association of Urology Guideline Practice Across Europe
5. CALGB 90203 (Alliance), Journal of Clinical Oncology -- Radical prostatectomy (RP) with or without neoadjuvant chemohormonal therapy (CHT) in men with clinically localized, high-risk prostate cancer (CLHRPC).
6. EAU Guidelines on Prostate Cancer - TREATMENT, Uroweb -- EAU Guidelines on Prostate Cancer
7. The ASCO Post — Accrual of Older Patients to Breast Cancer Trials: A Critical Need
8. Mapping European Association of Urology Guideline Practice Across Europe: An Audit of Androgen Deprivation Therapy Use Before Prostate Cancer Surgery in 6598 Cases in 187 Hospitals Across 31 European Countries - PubMed
9. CALGB 90203 (Alliance): Radical prostatectomy (RP) with or without neoadjuvant chemohormonal therapy (CHT) in men with clinically localized, high-risk prostate cancer (CLHRPC). | Journal of Clinical Oncology
10. EAU Guidelines on Prostate Cancer - TREATMENT - Uroweb